Greater Manchester and Cheshire HPB Unit
Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease
Chapter 1
Mission Statement
of the Greater Manchester & Cheshire HPB Unit,
CMFT

The HPB service in Manchester seeks to serve all equally, honestly and well and with skill and compassion.

Our service should be readily accessible, flexible and fair.

Our outcomes should be honestly, clearly and regularly reported.

We should contribute to the better understanding of HPB.

Ajith Siriwardena MD FRCS
Professor of Hepatobiliary Surgery, University of Manchester
Consultant and Lead Clinician HPB Unit, Manchester Royal Infirmary.
Cancer Lead Clinician, CMFT.
# Contents

1. **Introduction**  
2. **The Greater Manchester & Cheshire HPB sMDT**  
   2.1. A description of the GM&C HPB sMDT service  
   2.2. NHS England Strategic Clinical Network (SCN), Greater Manchester, Lancashire & South Cumbria  
   2.3. Greater Manchester Clinical Commissioning Groups (CCG’s)  
   2.4. Greater Manchester & Cheshire Trusts and Acute Hospitals  
3. **HPB cancer service in Greater Manchester and Cheshire - Model of Care**  
   3.1. Introduction  
   3.2. Leadership  
   3.3. Patient Pathway  
   3.4. Joint Working  
   3.5. Local Services  
   3.6. Transport  
   3.7. Audit of Outcomes  
4. **Manchester Cancer Pathways**  
   4.1. Manchester Cancer  
   4.2. Strategies for improving outcomes in HPB cancer  
   4.3. Suspected Cancer Referral Pathway Liver, Pancreas & Bile Duct  
   4.4. Manchester Cancer Investigations Pathway for Jaundice  
   4.5. Guidelines for referral of patients with known or suspected colorectal liver metastases  
   4.6. Criteria for referral of a patient with suspected HPB malignancy to the merged Greater Manchester specialist HPB MDT  
5. **Assessment & Management of Liver Metastases**  
   5.1. Metachronous colorectal liver metastases (CRLM) staging algorithm  
   5.2. Metachronous CRLM Treatment Algorithm  
   5.3. Treatment order algorithm for synchronous CRLM  
   5.4. Timing of treatment of synchronous CRLM  
   5.5. Resection of patients with extrahepatic disease  
   5.6. Consent  
   5.7. Cardiopulmonary Exercise Testing Protocol  
   5.8. Radiological Reporting Standards for CRLM  
   5.9. Histopathology reporting proforma – Colorectal cancer metastasis  
   5.10. Follow up after liver resection  
   5.11. Treatment of Metastatic Neuroendocrine Tumours  
   5.12. Management of GIST  
   5.13. Treatment of liver metastases of unknown primary  
   5.14. ECOG / WHO Performance Status  
   5.15. Differentiation of human epithelial neoplasms based on Immunohistochemistry  
6. **Hepatocellular carcinoma**  
   6.1. Introduction:  
   6.2. HCC surveillance  
   6.3. Screening for underlying liver disease:
### 6. HCC Management

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis of HCC</td>
<td>66</td>
</tr>
<tr>
<td>Staging of HCC</td>
<td>67</td>
</tr>
<tr>
<td>Surgical Resection</td>
<td>68</td>
</tr>
<tr>
<td>Liver Transplantation</td>
<td>68</td>
</tr>
<tr>
<td>Local Ablation:</td>
<td>69</td>
</tr>
<tr>
<td>Chemoembolisation and other transcatheter therapies</td>
<td>70</td>
</tr>
<tr>
<td>Systemic therapy</td>
<td>71</td>
</tr>
<tr>
<td>Advanced disease:</td>
<td>72</td>
</tr>
<tr>
<td>Long term follow-up:</td>
<td>72</td>
</tr>
<tr>
<td>EASL-EORTC Surveillance recall policy and diagnostic algorithm</td>
<td>73</td>
</tr>
<tr>
<td>Barcelona Clinic Liver Cancer strategy for diagnosis and staging of HCC</td>
<td>74</td>
</tr>
<tr>
<td>TNM classification and histopathology reporting proforma – HCC</td>
<td>76</td>
</tr>
<tr>
<td>Reporting proforma for liver resection: hepatocellular carcinoma</td>
<td>77</td>
</tr>
</tbody>
</table>

### 7. Benign liver conditions

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyogenic liver abscess</td>
<td>80</td>
</tr>
<tr>
<td>Management of hydatid cysts (cystic echinococcosis)</td>
<td>81</td>
</tr>
<tr>
<td>Solitary &amp; Polycystic liver disease</td>
<td>86</td>
</tr>
<tr>
<td>Hepatocellular adenomas</td>
<td>88</td>
</tr>
<tr>
<td>Acute Liver Failure</td>
<td>90</td>
</tr>
<tr>
<td>Liver Transplantation: UK Selection Criteria</td>
<td>92</td>
</tr>
</tbody>
</table>

### 8. Perihilar and intrahepatic cholangiocarcinoma

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSG Guidelines for cholangiocarcinoma screening in primary sclerosing cholangitis</td>
<td>94</td>
</tr>
<tr>
<td>Diagnosis and staging algorithm for cholangiocarcinoma</td>
<td>94</td>
</tr>
<tr>
<td>The De Oliveira-Clavien (B,T,F,PV,HA,V,D,N,M) Classification System</td>
<td>95</td>
</tr>
<tr>
<td>Criteria for unresectability</td>
<td>96</td>
</tr>
<tr>
<td>Treatment algorithm for resectable disease</td>
<td>97</td>
</tr>
<tr>
<td>Treatment algorithm for unresectable disease</td>
<td>98</td>
</tr>
<tr>
<td>TNM classification and histopathology reporting proforma – Perihilar cholangiocarcinoma</td>
<td>99</td>
</tr>
<tr>
<td>TNM Classification and histopathology reporting proforma – Intrahepatic cholangiocarcinoma</td>
<td>102</td>
</tr>
</tbody>
</table>

### 9. Management of Gallbladder Disease

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gallbladder polyps</td>
<td>106</td>
</tr>
<tr>
<td>Laparoscopic Cholecystectomy</td>
<td>107</td>
</tr>
<tr>
<td>Patient readmitted post-laparoscopic cholecystectomy</td>
<td>110</td>
</tr>
<tr>
<td>Bile duct injury</td>
<td>111</td>
</tr>
<tr>
<td>Diagnosis and staging of gallbladder cancer</td>
<td>119</td>
</tr>
<tr>
<td>Treatment algorithm for Gallbladder Cancer</td>
<td>120</td>
</tr>
<tr>
<td>Management of incidentally detected gallbladder cancer</td>
<td>121</td>
</tr>
<tr>
<td>Extent of surgery for Gallbladder cancer</td>
<td>122</td>
</tr>
<tr>
<td>TNM classification and histopathology reporting proforma – Gallbladder cancer</td>
<td>123</td>
</tr>
</tbody>
</table>

### 10. Acute Pancreatitis

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis</td>
<td>127</td>
</tr>
<tr>
<td>Initial Management</td>
<td>127</td>
</tr>
<tr>
<td>Definitions</td>
<td>127</td>
</tr>
<tr>
<td>Severity Prediction</td>
<td>130</td>
</tr>
<tr>
<td>Determine and treat the underlying aetiology</td>
<td>130</td>
</tr>
<tr>
<td>Role of ERCP</td>
<td>130</td>
</tr>
<tr>
<td>CT Scanning &amp; Ultrasound</td>
<td>130</td>
</tr>
</tbody>
</table>
10.8. Nutritional Support
10.9. Antibiotics
10.10. Management of gallstones
10.11. Management of alcoholism
10.12. Management of idiopathic acute pancreatitis
10.13. Management of Abdominal Compartment Syndrome
10.15. Indications for Referral to the specialist centre
10.16. Radiology Guidelines in Acute Pancreatitis

11. Chronic Pancreatitis
11.1. Overview of management
11.2. Diagnostic algorithm for chronic pancreatitis
11.3. Aetiological Classification of Chronic Pancreatitis (TIGAR-O system)
11.4. Treatment algorithm for chronic pancreatitis
11.5. Nutritional Assessment, Treatment of PEI and Type 3c DM
11.6. Autoimmune Pancreatitis – Principles of Diagnosis
11.7. Autoimmune Pancreatitis – Treatment Algorithm

12. Pancreatic cystic lesions
12.1. Classification and salient features of the more common pancreatic cystic lesions
12.2. Radiological reporting standards for pancreatic cystic lesions
12.3. Algorithm for management of pancreatic cystic lesions

13. Pancreatic cancer
13.1. Algorithm for diagnosis and staging of pancreatic cancer
13.2. Algorithm for treatment of pancreatic cancer
13.3. Secondary screening for early pancreatic cancer
13.4. Pancreatic cancer CT Staging
13.5. TNM and JPS classification – pancreatic, ampullary and bile duct cancer
13.6. Histopathology reporting proforma – Pancreatic carcinoma
13.7. Histopathology reporting proforma – Ampulla of Vater Cancer
13.8. Histopathology reporting proforma – Bile duct carcinoma

14. Neuroendocrine Tumours
14.1. Diagnostic algorithm for pancreatic neuroendocrine tumours (PNETs)
14.2. Management of PNET
14.3. Surgical management of resectable PNET
14.4. Management of Residual/Progressive/Metastatic/Inoperable PNET
14.5. ENETS TNM and WHO classification of PNET
14.6. Histopathology reporting proforma for pancreatic neuroendocrine tumour resections

15. General perioperative management
15.1. HPB WHO Checklist
15.2. ERAS Protocol for management of liver resection
15.3. ERAS Protocol for perioperative management of Pancreatoduodenectomy
15.4. Algorithm for reducing the risk of venous thromboembolism
15.5. Algorithm for IV fluid therapy
15.6. Acute Kidney Injury
15.7. Composition of commonly used crystalloids
15.8. Composition of common fluid losses
15.9. Malnutrition Universal Screening Tool (MUST) 184
15.10. Indications for nutrition support 185
15.11. Nutritional Support and Refeeding syndrome 186
15.12. Protocol for nutritional, anthropometric and clinical monitoring of nutrition support 188
15.13. Protocol for laboratory monitoring of nutrition support 191
15.14. HPB Quality Improvement Programme (QIP) 193

16. HPB trauma 198
16.2. Operative management of blunt hepatic trauma 201
16.3. Non-operative management of adult blunt hepatic trauma 202
16.4. Management of pancreatic injuries 203
16.5. AAST Liver Injury Scale 204
16.6. AAST Pancreas Organ Injury Scale 204

17. Selected References 205
1. Introduction
The purpose of this guideline document is to aid better decision making. In medicine, we pride ourselves on our ability to produce quick and intuitive “end of the bed diagnoses” and answers to clinical questions. When tested against simple formulae, the response of experts is (almost always) inferior. Hence, these guidelines are a collection of formulae, algorithms and checklists that have been taken from the latest evidence based guidelines from the relevant specialist associations.

A second purpose is to fulfil our requirements to regulatory bodies. The Greater Manchester Cancer Summit 2012 determined that the Hepato-pancreato-biliary (HPB) surgical service for Greater Manchester and Cheshire patients should be established on a single acute hospital site and developed in a way that is fully compliant with national Improving Outcomes Guidance (IOG). In October 2014, the HPB services, provided by Pennine Acute Trust (PAT) at North Manchester General Hospital and by Central Manchester Foundation Trust, merged and moved to the Manchester Royal Infirmary (MRI) site at CMFT, creating a single specialist site for Greater Manchester and Cheshire patients. The rationale for this merger of services onto a single site is to create the best conditions for the development of the service as ‘world class’, improving both the quality of service provided and outcomes for patients through the centralisation and concentration of expertise and facilities on one hospital site. The Cancer Summit document, “The Delivery of World Class Specialist Cancer Surgery Services in the Greater Manchester and Cheshire Cancer System - A Framework Commissioning Specification, Jan 2013” states “each service must have a single set of governance arrangements, clinical guidelines, a single pathway and operational policy”. This guideline document fulfils that role, as well as meeting similar requirements from National Cancer Peer Review and NHS Commissioning Board Service Specifications.

The decision to produce this document was made by the Joint Implementation Group that oversaw the merger of the two Manchester HPB units. It was achieved by the following process: members of the North Manchester and MRI HPB MDTs and other interested parties met at a series of meetings over the course of 2013-14; the scope of the work was outlined; subgroups drafted their chapters, which were reviewed and amended by e-mail and at subsequent meetings; widespread consultations of all interested parties was achieved through the Manchester Cancer HPB Pathway Board; before final submission to the CMFT clinical governance committee.

Acknowledgements are due to all those who participated at these meetings and/or contributed to the production of these guidelines: Prof. Ajith Siriwardena, Mr. Aali Sheen, Mr. Thomas Satyadas, Mr. Saurabh Jamdar, Mr. Derek O’Reilly, Mr. Rahul Deshpande, Mr. Nicola De’Liguori Carino, Dr. Steven Lee, Dr. Rishi Sethi, Dr. Rafik Filobbos, Dr. Zahir Sherazi, Dr Eddie Tam, Dr Hans Ulrich Laasch, Sr. Debbie Clark, Dr. Alistair
Makin, Dr. Jo Puleston, Dr. Luke Williams, Dr. Richard Hammonds, Dr. Martin Prince, Dr. Shaun Greer, Prof. Juan Valle, Dr. Richard Hubner, Dr. Saiffee Mullimitha, Dr. Michael Braun, Dr. Mark Saunders, Dr. Vivek Misra, Dr. Catherine McBain, Dr. Greg Wilson, Dr. Hassan Jurjees, Dr. Angela Lamarca, Dr. Mairead McNamara, Dr. Prakesh Manoharan, Dr. Mike Leahy, Dr. Claire Mitchell, Dr. Stephen McGrath and Dr. Emyr Benbow. Thanks are due to those junior medical staff whose greater computer literacy was availed of in the production of this guidance: Mr. Munir Junejo, Ms. Jen Barrie, Dr. Tom Lee, Mr. Sot Tolofari, Miss Hema Sekhar, Mr. Mazier Khorshandi, Mr. Neil Harvey, Mr. Peter Coe, and especially to Mr. Vishnu V Chandrabalan for his tireless contribution in maintaining and developing this document. Special thanks are also due to: Mrs. Sarah Duff and Mr. Marc Besselink, who both were guest speakers at our guidelines meetings and to: Prof. Colin Johnson, Dr. Stephen Pereira and Mr. Marc Besselink for sharing draft international guidelines in development. My sincere apologies to anyone that I have inadvertently forgotten to thank.

Derek O’Reilly,
Consultant HPB Surgeon,
Manchester,
September 2014.
Disclaimer

The information contained within, including but not limited to clinical practice guidelines and other guidance, is based on the best available evidence at the time of creation and is provided by CMFT/Manchester Cancer to assist providers in clinical decision making. The information should not be relied on as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. These guidelines are due for revision in January 2018. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular product or course of medical treatment. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in certain cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. CMFT/Manchester Cancer provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. CMFT/Manchester Cancer specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. CMFT/Manchester Cancer assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.